van Kleef, J. J.
Dijksterhuis, W. P. M. http://orcid.org/0000-0002-3516-6743
van den Boorn, H. G.
Prins, M.
Verhoeven, R. H. A.
Gisbertz, S. S.
Slingerland, M.
Mohammad, N. Haj
Creemers, G.-J.
Neelis, K. J.
Heisterkamp, J.
Rosman, C.
Ruurda, J. P.
Kouwenhoven, E. A.
van de Poll-Franse, L. V.
van Oijen, M. G. H.
Sprangers, M. A. G.
van Laarhoven, H. W. M.
,
Funding for this research was provided by:
Dutch Cancer Society (UVA 2014-7000)
Article History
Received: 26 February 2021
Accepted: 29 June 2021
First Online: 12 July 2021
Declarations
:
: RHAV reports grants from BMS and Roche. NHM reports a consult/advisory role for BMS, MSD Servier, Eli Lilly, Astra Zeneca, research grant from Servier. MGHvO reports grants from Amgen, BMS, Lilly, Nordic, Merck, Roche, and Servier. HWMvL reports a consult/advisory role for BMS, Celgene, Lilly, Merck, Nordic, and Servier and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, Roche and Servier. The other authors declare that they have no conflicts of interest.
: According to the Central Committee on Research Involving Human Subjects, this type of study does not require approval from an ethics committee in the Netherlands. The study was approved by the Privacy Review Board of the Netherlands Cancer Registry and the scientific committee of the Dutch Upper GI Cancer Group. Patients who participated in the Prospective Observational Cohort Study of Oesophageal-Gastric Cancer Patients (POCOP) provided written informed consent.